Journal
CHEST
Volume 123, Issue 5, Pages 500S-503SPublisher
AMER COLL CHEST PHYSICIANS
DOI: 10.1378/chest.123.5_suppl.500S
Keywords
candidemia; epidemiology; fluconazole; prophylaxis
Categories
Ask authors/readers for more resources
The incidence of candidemia-a common and potentially fatal nosocomial infection-has risen dramatically, and this increase has been accompanied by a shift in the infecting pathogen away from Candida albicans to treatment-resistant non-albicans species. Prophylactic azole antifungals, such as fluconazole, may play an important role not only in the management of candidemia but also in the proliferation of hard-to-treat Candida species. In a variety of acute nosocomial settings, IV fluconazole, 400 mg/d, has reduced Candida colonization and infection. A growing body of evidence supports the still controversial contention that the increasing use of azole antifungals is at least partially responsible for the proliferation of treatment-resistant, non-albicans isolates, especially Candida glabrata. Thus, selecting the most appropriate candidates for prophylactic antifungal intervention-ie, those with the highest risk for candidemia-may be indispensable, not only in preventing candidemia, but also in reducing antifungal overuse, which may contribute to the emergence of treatment-resistant Candida isolates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available